Associate Professor Tom Scriba has co authored a paper titled "Can we predict tuberculosis cure? What tools are available?" appearing in the European Respiratory Journal of the European Respiratory Society.
Watch the press conference during which the primary results from the M72/AS01E candidate vaccine were announced during the Union World Conference on Lung Health. Professor Mark Hatherill, SATVI Director spoke on behalf of SATVI.
View the full list of SATVI speakers at the The Union World Conference on Lung Health held from 24 to 27 October 2018.
The New England Journal of Medicine has just published the primary results of an ongoing phase IIb clinical trial testing the candidate tuberculosis vaccine M72/AS01E which demonstrates that the M72/AS01E vaccine significantly reduced the incidence of pulmonary tuberculosis disease in HIV-negative adults who were already infected with latent TB at the time of vaccination.